A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer

Right now, we are studying MEN2312 to see if it can help people with advanced breast cancer. We want to find out if it is safe, if people can tolerate it, how the body handles it, and if it starts to work against cancer, both on its own alone in the Part A and Part B and when used with other cancer drugs in the other parts of the study (Parts C - F).